Global Cord Blood Banking Industry Report 2020: Trends, Expansion Technologies, Key Strategies, Regional Insights
31 août 2020 06h59 HE
|
Research and Markets
Dublin, Aug. 31, 2020 (GLOBE NEWSWIRE) -- The "Global Cord Blood Banking Industry Report 2020" report has been added to ResearchAndMarkets.com's offering.This report presents the number of cord...
Acute Myeloid Leukemia Therapeutics Market To Reach USD 3.56 Billion By 2027 | Reports And Data
22 juil. 2020 15h04 HE
|
Reports and Data
New York, July 22, 2020 (GLOBE NEWSWIRE) -- Market Size – USD 1.46 Billion in 2019, Market Growth - CAGR of 13.1%, Market Trends – Implementing various growth strategies in therapeutics. New York,...
Bellicum Pharmaceuticals Presents Encouraging Preclinical Data for GoCAR-NK Cell Program at Society for Immunotherapy of Cancer Annual Meeting
08 nov. 2019 07h00 HE
|
Bellicum Pharmaceuticals, Inc.
iMC activation enhances innate NK cell cytotoxicity against tumor cell lines in vitro MC activity enhances the efficacy of CAR-NK cells against hematological and solid tumor models MC signaling...
Bellicum Pharmaceuticals Reports Third Quarter 2019 Financial Results and Provides Operational Update
06 nov. 2019 16h15 HE
|
Bellicum Pharmaceuticals, Inc.
Raised gross proceeds of $69.6 million from public offering and private placement option fee Narrowed strategic focus to core GoCAR-T® cell therapy programs Cost saving initiatives underway to...
Bellicum Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
30 sept. 2019 16h07 HE
|
Bellicum Pharmaceuticals, Inc.
HOUSTON, Sept. 30, 2019 (GLOBE NEWSWIRE) -- Bellicum Pharmaceuticals, Inc. (NASDAQ:BLCM), a leader in developing novel, controllable cellular immunotherapies for cancers and orphan inherited blood...
Bellicum Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
30 août 2019 16h08 HE
|
Bellicum Pharmaceuticals, Inc.
HOUSTON, Aug. 30, 2019 (GLOBE NEWSWIRE) -- Bellicum Pharmaceuticals, Inc. (NASDAQ:BLCM), a leader in developing novel, controllable cellular immunotherapies for cancers and orphan inherited blood...
Bellicum Pharmaceuticals to Participate in Three Healthcare Investor Conferences during September
28 août 2019 16h05 HE
|
Bellicum Pharmaceuticals, Inc.
HOUSTON, Aug. 28, 2019 (GLOBE NEWSWIRE) -- Bellicum Pharmaceuticals, Inc. (NASDAQ:BLCM), a leader in developing novel, controllable cellular immunotherapies for cancers and orphan inherited blood...
Bellicum Pharmaceuticals Announces Aggregate Gross Proceeds of $69.6 Million from $139.6 Million Public Offering and Private Placement
21 août 2019 16h05 HE
|
Bellicum Pharmaceuticals, Inc.
HOUSTON, Aug. 21, 2019 (GLOBE NEWSWIRE) -- Bellicum Pharmaceuticals, Inc. (Nasdaq: BLCM), a leader in developing novel, controllable cellular immunotherapies for cancers and orphan inherited blood...
Bellicum Pharmaceuticals Announces Proposed $53.0 Million Public Offering of Preferred Stock and Warrants with Concurrent Private Placement
15 août 2019 17h37 HE
|
Bellicum Pharmaceuticals, Inc.
HOUSTON, Aug. 15, 2019 (GLOBE NEWSWIRE) -- Bellicum Pharmaceuticals, Inc. (Nasdaq: BLCM), a leader in developing novel, controllable cellular immunotherapies for cancers and orphan inherited blood...
Bellicum Pharmaceuticals Reports Second Quarter 2019 Financial Results and Provides Operational Update
05 août 2019 16h15 HE
|
Bellicum Pharmaceuticals, Inc.
Interim safety and activity data for BPX-601 presented at American Society of Clinical Oncology (ASCO) Annual Meeting Rivo-celTM achieved primary endpoint in BP-004 European registrational trial ...